Research & Development
US court approves Indivior's preliminary injunction preventing Dr Reddy's Laboratories from marketing generic opioid addiction treatment
18 July 2018 - A US court has approved United Kingdom-based Indivior's preliminary injunction preventing Dr Reddy's Laboratories from marketing of generic opioid addiction treatment, it was ...
Ironwood Pharmaceuticals commences phase IIIb clinical trial of linaclotide 290 mcg
18 July 2018 - United States-based Ironwood Pharmaceuticals has commenced a phase IIIb clinical trial assessing the efficacy and safety of linaclotide 290 mcg on multiple abdominal symptoms in additio...
Candela Corporation wins US FDA clearance for next level dermatologic 595 nm pulsed dye laser, Vbeam Prima
18 July 2018 - Aesthetic device company Candela Corporation reported on Tuesday the receipt of US Food and Drug Administration (FDA) clearance for Vbeam Prima, its advanced next level dermatologic 595...
NICE Recommends Treatment with Quarziba in High-Risk Neuroblastoma
17 July 2018 - - The National Institute for Health and Care Excellence (NICE) has recommended the use of the targeted cancer immunotherapy Qarziba (dinutuximab beta), being investigated by Hemel Hemps...
Camurus receives PDUFA date for CAM2038 for the treatment of opioid use disorder
17 July 2018 - Camurus AB (STO: CAMX), a Swedish research-based pharmaceutical company, announced on Monday the assignment by the US Food and Drug Administration (FDA) of a Prescription Drug User Fee ...
The Foundation Fighting Blindness names Russell Kelley as VP of Investments and Alliances
17 July 2018 - Retinal degenerative company The Foundation Fighting Blindness (FFB) revealed on Monday the election of Russell Kelley, PhD, MBA as vice president of its investments & alliances.In ...